46.50
-5.10%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai HeartCare Medical Technology Corp
Its shares trade on HKEX under the ticker 6609.HK. It has been listed since 20 August 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥408.3m and net income of CN¥83.3m. At that date it held total assets of CN¥1.29bn and shareholders' equity of CN¥1.13bn.
Shanghai Heartcare Medical Technology Corp. Ltd. engages in the research, development, manufacture, and sale of neuro-interventional medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-08-20. The firm's product portfolio includes both neuro-interventional and cardiac medical devices, and its main products are CaptorTM thrombectomy device (Captor) and left atrial appendage occluder. The firm's product portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis to the treatment of hemorrhagic stroke. The firm's other products include the balloon guiding catheter, the ExtraFlex distal access catheter and SupSelek microcatheter. The firm distributes its products within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 20 Aug 2021
- Employees
- 453
- Website
- heartcare.com.cn ↗
Leadership
Pay as last reported
- Mr. Guohui WangExecutive Chairman of the Board, Chief Executive Officer, since 2016
- Mr. Han ZhangChief Financial Officer, Joint Company Secretary
- Mr. Jiawei WeiDeputy General Manager, Executive Director, since 2020
- Ms. Kun ZhangDeputy General Manager, Executive Director, since 2020
- Dr. Zhigang LiDeputy General Manager
- Ms. Siu Ying KwokJoint Company Secretary
- Mr. Gang ChenNon-Executive Director
- Mr. Shaoxiong ChenNon-Executive Director
- Mr. Kui DingNon-Executive Director
- Mr. Xiangqian FengIndependent Non-Executive Director
- Mr. Ping GongIndependent Non-Executive Director
- Mr. Shaomu GuoIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai HeartCare Medical Technology Corp Ltd employs 453 skilled employees in Shanghai.
- The company's product portfolio includes CaptorTM thrombectomy device and left atrial appendage occluder.
- Shanghai HeartCare focuses on neuro-interventional and cardiac medical devices for stroke treatment.
Weaknesses
- The company distributes products only within the domestic market in China.
- Shanghai HeartCare has no international presence or global distribution channels.
- The firm's product range is limited to stroke treatment and prevention.
Opportunities
- Shanghai HeartCare could expand into international markets beyond China.
- The growing demand for stroke treatment devices in China presents opportunities.
- Shanghai HeartCare may develop new products for cardiac and neuro-interventional markets.
Threats
- The company faces competition from domestic medical device manufacturers in China.
- Shanghai HeartCare's reliance on the domestic market increases vulnerability to local economic changes.
- Regulatory changes in China's healthcare sector could impact product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.